Lv3
214 积分 2023-01-29 加入
Efficacy of dual KRASG12D–EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer
2个月前
已完结
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
5个月前
已完结
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
5个月前
已完结
A model for RAS mutation patterns in cancers: finding the sweet spot
6个月前
已完结
Tertiary lymphoid structures in cancer
9个月前
已完结
Intratumoral Injection of R848 and Poly(I:C) Synergistically Promoted Antitumour Immune Responses by Reprogramming Macrophage Polarization and Activating DCs in Lung Cancer
9个月前
已完结
Molecular glue meets antibody: next-generation antibody–drug conjugates
9个月前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
9个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
9个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
9个月前
已完结
皖公网安备34019202002308
